CIK 0000860730 · Large accelerated filer
HCA Healthcare, Inc.
Sign in to watch- Ticker
- HCA
- Exchange
- NYSE
- Industry
- Services-General Medical & Surgical Hospitals, NEC
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 273865930
- Phone
- 6153449551
- Business address
- ONE PARK PLZ, NASHVILLE, TN, 37203
- Former names
- HCA Holdings, Inc., HCA INC/TN, HCA THE HEALTHCARE CO, HCA-THE HEALTHCARE CO, COLUMBIA HCA HEALTHCARE CORP, COLUMBIA HCA HEALTHCARE CORP/, COLUMBIA HEALTHCARE CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $18,251,400
- in 3 filings
Net −$18,251,400. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-05 | Wyatt Christopher F. SVP & Controller | Shares withheld for taxes | −5,674 | $513.76 | $2.9M | 46,063 |
| 2026-02-05 | Wyatt Christopher F. SVP & Controller | Option exercise · Stock Appreciation Right | −10,670 | 0 | ||
| 2026-02-05 | Foster Jon M EVP and COO | Option exercise | +29,330 | $139.06 | $4.1M | 29,330 |
| 2026-02-05 | Foster Jon M EVP and COO | Shares withheld for taxes | −16,076 | $513.76 | $8.3M | 13,254 |
| 2026-02-05 | Foster Jon M EVP and COO | Option exercise · Stock Appreciation Right | −29,330 | 0 | ||
| 2026-02-04 | HAZEN SAMUEL N CEO | Other disposition | −1,045 | $498.35 | $521K | 31,231 |
| 2026-02-04 | HAZEN SAMUEL N CEO | Other acquisition | +1,045 | $498.35 | $521K | 16,024 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −14,716 | $502.95 | $7.4M | 60,437 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −5,002 | $502.15 | $2.5M | 55,435 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −7,395 | $500.69 | $3.7M | 48,040 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −6,189 | $500.02 | $3.1M | 41,851 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −5,162 | $498.80 | $2.6M | 36,689 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −4,293 | $498.12 | $2.1M | 32,396 |
| 2026-02-03 | HAZEN SAMUEL N CEO | Sale | −120 | $497.18 | $60K | 32,276 |
| 2026-02-03 | Cuffe Michael S. EVP and Chief Clinical Officer | Sale | −1,500 | $498.09 | $747K | 30,002.9 |
| 2026-02-03 | Cuffe Michael S. EVP and Chief Clinical Officer | Gift | −4,050 | 25,952.9 | ||
| 2026-01-30 | HAZEN SAMUEL N CEO | Option exercise | +84,360 | $81.96 | $6.9M | 116,636 |
| 2026-01-30 | HAZEN SAMUEL N CEO | Shares withheld for taxes | −41,483 | $488.27 | $20.3M | 75,153 |
| 2026-01-30 | HAZEN SAMUEL N CEO | Option exercise · Stock Appreciation Right | −84,360 | 0 | ||
| 2026-01-29 | Wyatt Christopher F. SVP & Controller | Grant or award · Stock Appreciation Right | +2,560 | 2,560 |
Page 5 of 56 · 1,102 trades